ADMA Biologics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
ADMA Biologics has been growing earnings at an average annual rate of 19.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 49.8% per year. ADMA Biologics's return on equity is 18.5%, and it has net margins of 10.5%.
Anahtar bilgiler
19.1%
Kazanç büyüme oranı
43.2%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | 49.8% |
Özkaynak getirisi | 18.5% |
Net Marj | 10.5% |
Sonraki Kazanç Güncellemesi | 07 Nov 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18Gelir ve Gider Dağılımı
ADMA Biologics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 330 | 35 | 65 | 2 |
31 Mar 24 | 283 | -4 | 63 | 3 |
31 Dec 23 | 258 | -28 | 63 | 3 |
30 Sep 23 | 234 | -23 | 65 | 4 |
30 Jun 23 | 208 | -40 | 69 | 4 |
31 Mar 23 | 182 | -48 | 69 | 4 |
31 Dec 22 | 154 | -66 | 70 | 4 |
30 Sep 22 | 130 | -70 | 68 | 2 |
30 Jun 22 | 110 | -73 | 64 | 2 |
31 Mar 22 | 94 | -78 | 61 | 2 |
31 Dec 21 | 81 | -72 | 55 | 3 |
30 Sep 21 | 69 | -74 | 49 | 4 |
30 Jun 21 | 58 | -74 | 46 | 5 |
31 Mar 21 | 48 | -75 | 43 | 5 |
31 Dec 20 | 42 | -76 | 39 | 6 |
30 Sep 20 | 40 | -67 | 36 | 5 |
30 Jun 20 | 37 | -61 | 33 | 4 |
31 Mar 20 | 36 | -54 | 30 | 3 |
31 Dec 19 | 29 | -48 | 28 | 2 |
30 Sep 19 | 21 | -56 | 29 | 3 |
30 Jun 19 | 18 | -59 | 29 | 3 |
31 Mar 19 | 16 | -61 | 29 | 4 |
31 Dec 18 | 17 | -66 | 30 | 4 |
30 Sep 18 | 18 | -61 | 30 | 4 |
30 Jun 18 | 18 | -61 | 28 | 5 |
31 Mar 18 | 17 | -55 | 23 | 5 |
31 Dec 17 | 16 | -44 | 21 | 6 |
30 Sep 17 | 14 | -35 | 18 | 5 |
30 Jun 17 | 12 | -24 | 16 | 5 |
31 Mar 17 | 11 | -21 | 17 | 7 |
31 Dec 16 | 11 | -20 | 14 | 8 |
30 Sep 16 | 10 | -20 | 12 | 9 |
30 Jun 16 | 9 | -20 | 12 | 10 |
31 Mar 16 | 8 | -19 | 12 | 8 |
31 Dec 15 | 7 | -18 | 11 | 7 |
30 Sep 15 | 6 | -17 | 11 | 7 |
30 Jun 15 | 6 | -15 | 9 | 6 |
31 Mar 15 | 6 | -15 | 9 | 7 |
31 Dec 14 | 6 | -17 | 9 | 10 |
30 Sep 14 | 5 | -18 | 8 | 11 |
30 Jun 14 | 5 | -17 | 8 | 10 |
31 Mar 14 | 4 | -18 | 7 | 12 |
31 Dec 13 | 3 | -16 | 7 | 9 |
Kaliteli Kazançlar: ADMA has a large one-off loss of $29.0M impacting its last 12 months of financial results to 30th June, 2024.
Büyüyen Kar Marjı: ADMA became profitable in the past.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ADMA has become profitable over the past 5 years, growing earnings by 19.1% per year.
Büyüme Hızlandırma: ADMA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Kazançlar vs. Sektör: ADMA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: ADMA's Return on Equity (18.5%) is considered low.